SCHEMBL5311900

SCHEMBL5311900

CN1CCN(c2cc(F)cc3c2OC(C(=O)Nc2ccc(N4CCCN(C)C4=O)cc2)CC3)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR1B P28222 6/20 0.57
▸ KCNH2 Q12809 1/20 0.57
▸ FPR2 P25090 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ NFKB1 P19838 5/20 0.35
▸ NFKB2 Q00653 5/20 0.35
▸ RELA Q04206 5/20 0.35
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR1D P28221 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ WDR5 P61964 2/20 0.34
▸ NPY5R Q15761 1/20 0.34
▸ PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469032 0.91 HTR1B (0.54) HTR1BKCNH2FPR2SMN1; SMN2KDM4E
SCHEMBL5308374 0.90 HTR1B (0.59) HTR1BKCNH2FPR2SMN1; SMN2KDM4E
SCHEMBL5310564 0.89 HTR1B (0.74) HTR1BKCNH2SMN1; SMN2KDM4ENFKB1
SCHEMBL14530380 0.88 HTR1B (0.55) HTR1BKCNH2FPR2SMN1; SMN2KDM4E
SCHEMBL4250243 0.88 HTR1B (0.71) HTR1BKCNH2SMN1; SMN2NFKB1NFKB2
SCHEMBL5308402 0.88 HTR1B (0.57) HTR1BKCNH2FPR2SMN1; SMN2KDM4E
SCHEMBL5309254 0.86 HTR1B (0.60) HTR1BKCNH2SMN1; SMN2KDM4ERXFP1
SCHEMBL5308377 0.85 HTR1B (0.57) HTR1BKCNH2SMN1; SMN2KDM4ERXFP1
SCHEMBL5308451 0.85 HTR1B (0.78) HTR1BKCNH2SMN1; SMN2KDM4ERXFP1
SCHEMBL5332698 0.85 HTR1B (0.57) HTR1BKCNH2SMN1; SMN2KDM4ENFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US claimed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO claimed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135442-A1 Chroman compounds CYP3A43, CYP2C9, CYP2C8 HTR1B 592/4885KCNH2 1018/4885FPR2 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback